Real-World safety and effectiveness of evolocumab in primary hypercholesterolemia and mixed dyslipidemia in Saudi Arabia
Evolocumab appeared to be safe and effective therapeutic option for patients with primary hypercholesterolemia or mixed dyslipidemia to potentially reduce LDL levels to therapeutic levels when statins are insufficient.
Authors
- Majed S. Al Yami (ORCID: https://orcid.org/0000-0003-2308-8407)
- Alaa Bagalagel (ORCID: https://orcid.org/0000-0002-9909-4881)
- Omar A. Almohammed (ORCID: https://orcid.org/0000-0002-3792-4106)
- Awatif Hafiz
- Abdulaziz Alakeel (ORCID: https://orcid.org/0000-0002-9676-0738)
- Aisha Alharbi (ORCID: https://orcid.org/0000-0001-9981-3666)
- Abdulaali R. Almutairi (ORCID: https://orcid.org/0000-0002-3141-0606)
- Mashael S. Alaboud
- Walaa A Alshahrani
- Waddah Ashram
- Ghaida K Alhathlol
- Sarah Aljohani
- Hussam I. Kutbi (ORCID: https://orcid.org/0000-0002-4842-4430)
- Fatimah Alsheikh
- Mohammad Fouda
- Meshal S Alhamed
Institutions
- King Abdulaziz University (SA)
- King Saud bin Abdulaziz University for Health Sciences (SA)
- King Saud University (SA)
- King Abdulaziz Medical City (SA)
- Saudi Arabian Monetary Authority (SA)
- King Fahd Armed Forces Hospital (SA)
- King Abdulaziz Hospital (SA)
Publication Details
- Journal
- Saudi Pharmaceutical Journal
- Published
- 2024-11-04
- DOI
- https://doi.org/10.1016/j.jsps.2024.102203
- Citations
- 2
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 1.15
Funders
- King Saud University